RxDoctor Payments Data

Justina Thomas

Psychiatric/Mental Health · Beaumont, CANPI 1487351748

Payments from drug & device makers

$6,185in general payments, 2019–2025

Across 320 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$927
  • Otsuka America Pharmaceutical, Inc.$880
  • Johnson & Johnson$855
  • Neurocrine Biosciences, Inc.$817
  • AbbVie$718
  • Vanda Pharmaceuticals Inc.$678
  • plus $1K from 8 others

What the payments were for

  • Food & beverage$6,173100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,185 in reported general payments places this provider in the 90th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$9,939
Medicare patients
24
Services billed
85

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine13$80,665
RexultiBrexpiprazole14$19,689
Lisdexamfetamine Dimesylate12$2,543
Aripiprazole38$1,146
Quetiapine Fumarate44$599
Bupropion XlBupropion Hcl24$596
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine13$542
Trazodone Hcl44$497
Escitalopram Oxalate70$453
Olanzapine15$316
Buspirone Hcl38$303
Lorazepam29$269
Risperidone27$227
Duloxetine Hcl16$222
Prazosin Hcl19$215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$927$80,66513 claims
Otsuka America Pharmaceutical, Inc.Rexulti$880$19,68914 claims
Almatica Pharma LLCSertraline Hcl$70$19136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in Beaumont

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →